Home - Products - Others - Other Targets - KKI-5 TFA(97145-43-2 free base)

KKI-5 TFA(97145-43-2 free base)

CAS No. ——

KKI-5 TFA(97145-43-2 free base)( —— )

Catalog No. M30078 CAS No. ——

KKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    KKI-5 TFA(97145-43-2 free base)
  • Note
    Research use only, not for human use.
  • Brief Description
    KKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
  • Description
    KKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Kallikrein
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    887.9
  • Molecular Formula
    C37H56F3N11O11
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.
molnova catalog
related products
  • 7-(4-hydroxy-3-metho...

    7-(4-hydroxy-3-methoxyphenyl)-1-phenylhept-4-en-3-one (DPHB) is a natural product for research related to life sciences.

  • Z-D-E-V-D-AMC

    Z-D-E-V-D-AMC

  • KSC-34

    KSC-34 is a covalent modifier of protein disulfide isomerase A1 (PDIA1).KSC-34 is a selective inhibitor targeting the a-site of PDIA1.